Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

201TiP - Evaluation of the feasibility of ultrasound-guided clipping of suspicious intramammary lesions in primary breast cancer patients receiving neoadjuvant therapy (Ultra3Detect)


16 Sep 2021


ePoster Display


Efstathia Vlachou


Annals of Oncology (2021) 32 (suppl_5): S407-S446. 10.1016/annonc/annonc687


E. Vlachou1, S. Kümmel1, N. Künzel1, E. Breit1, D. Schindowski1, K. Pankert2, S. Hentsch3, V. Hanf4, D. Weber5, S. Graßhoff6, C. Müller7, W. Lucke8, P. Deuschle9, K. Engellandt10, A. Rüland11, P. Dall12, H. Harrach1, S. Bruzas1, O. Chiari1, M. Reinisch1

Author affiliations

  • 1 Breast Unit, Kliniken Essen-Mitte, 45136 - Essen/DE
  • 2 Breast Unit, Diakonissen-Stiftungs-Krankenhaus Speyer, 67346 - Speyer/DE
  • 3 Breast Unit, Städtisches Klinikum Solingen, 42653 - Solingen/DE
  • 4 Frauenklinik Nathanstift, Breast Unit Klinikum Fürth, 90766 - Fürth/DE
  • 5 Klinik Für Gynäkologie Und Geburtshilfe, St. Barbara-Klinik Hamm-Heessen, 59073 Hamm - Hamm/DE
  • 6 Breast Unit, Harzklinikum Dorothea Christiane Erxleben, 38855 - Wernigerode/DE
  • 7 Breast Unit, Kreiskrankenhaus Bergstraße, 64646 - Heppenheim/DE
  • 8 Breast Unit, Hegau-Bodensee-Klinikum, 78224 - Singen/DE
  • 9 Breast Unit, Marienhaus Klinikum Hetzelstift Neustadt/Weinstraße, 67434 - Neustadt an der Weinstraße/DE
  • 10 Breast Unit, Evangelisches Krankenhaus Bethesda zu Duisburg, 47053 - Duisburg/DE
  • 11 Breast Unit, St. Marien-Hospital Düren, 52353 - Düren/DE
  • 12 Brustzentrum Und Gynäkologisches Krebszentrum, Städtisches Klinikum Lüneburg gGmbH, 21339 - Lüneburg/DE

Abstract 201TiP


Neoadjuvant systemic chemotherapy (NST) is increasingly recommended for patients with early breast cancer, and the rate of cases with complete pathological remission (pCR) is on the rise due to the use of modern chemotherapy regimens and targeted therapies, especially in patients with human epidermal growth factor receptor 2 positive (HER2+) and triple-negative breast cancer (TNBC). It is, therefore, important to mark a lesion before the start of NST to ensure safe localization of the clip after completion of NST. In case of pCR, localization of the clip is often performed under mammographic control. Reliable sonographic detection and marking of the clip would be preferred, since a mammography implies additional radiation exposure and increased personnel, time, and financial expenditures. The present study aims to evaluate the sonographic detection rate (DR) of the intramammary Tumark® Vision clip after NST.

Trial design

The Ultra3Detect study (ClinicalTrials.gov ID: NCT04468113) is a multicenter, prospective, investigator initiated registry study. The study includes women aged ≥ 18 years with early breast cancer (cM0) and an indication for breast-conserving therapy and NST. Patients who are scheduled for marking of the lesion with the Tumark® Vision Clip (SOMATEX® Medical Technologies, Berlin, Germany) are eligible. Women with prior extensive breast surgery or those already undergoing adjuvant or neoadjuvant chemotherapy are excluded from the investigation. If the clip can be detected preoperatively by ultrasound, then ultrasound-guided wire marking is performed, otherwise stereotactic marking is required. The primary endpoint is the sonographic DR of Tumark® Vision clips at the time of surgery after completion of NST treatment of at least 12 weeks in patients with HER2+ and TNBC. Main secondary endpoints are the sonographic DRs during NST treatment at different time points (4–8, 9–12, ≥ 13 weeks), the intraoperative DR of the clip, and the proportion of cases in which mammography-guided wire marking can be avoided. Since the start of enrollment in May 2020, 104 patients (30% of target cohort) have been registered in 18 study centers.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Breast Unit, Kliniken Essen-Mitte.


Has not received any funding.


S. Kümmel: Financial Interests, Personal, Advisory Board: Lilly, Roche, Genomic Health, Novartis, Amgen, Celgene, Daiichi Sankyo, AstraZeneca, Somatex, MSD, Pfizer, PFM medical, Seagen; Financial Interests, Personal, Principal Investigator: Novartis, Somatex, Roche; Non-Financial Interests, Personal, Other, travel expenses: Roche, Daiichi Sankyo, Sonoscape. E. Breit: Financial Interests, Personal, Writing Engagements: Sysmex, Olympus, Merck Serono, Daiichi Sankyo. S. Hentsch: Financial Interests, Personal, Writing Engagements: Aesculap. A. Rüland: Financial Interests, Personal, Invited Speaker: Roche, Pfizer; Non-Financial Interests, Personal, Other, Travel expenses: Celgene. P. Dall: Financial Interests, Personal, Advisory Board: Roche, Novartis, Eisai, Hexal, Tesaro, Pierre Fabre, Amgen, Clovis, Olympus; Non-Financial Interests, Personal, Other, travel expenses: Clovis, Pierre Fabre, Olympus, Roche, Novartis, Tesaro, Hexal. M. Reinisch: Financial Interests, Personal, Advisory Board: Lilly, Roche, Novartis, Daiichi Sankyo, AstraZeneca, MSD, Pfizer, Seagen; Non-Financial Interests, Personal, Other, Travel expenses: Novartis, Celgene, Pfizer; Financial Interests, Personal, Invited Speaker: Somatex. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.